Adoption of once-monthly oral bisphosphonates and the impact on adherence

American Journal of Medicine

Volumn 123, Issue 3, 2010, Pages 275-280

  Briesacher, Becky A ^a   Andrade, Susan E ^a   Harrold, Leslie R ^a   Fouayzi, Hassan ^a   Yood, Robert A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Bisphosphonates; Novel formulation; Patient compliance

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; RISEDRONIC ACID;

AGED; ARTICLE; DRUG DOSE REGIMEN; FEMALE; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; OSTEOLYSIS; RETROSPECTIVE STUDY; STATISTICS;

ADMINISTRATION, ORAL; AGED; BONE RESORPTION; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES;

EID: 77950465582     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.05.017     Document Type: Article

References (22)

1. Chesnut IC, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241-1249. (Pubitemid 41094364)
2. Delmas PD, Recker RR, Chesnut CH 3rd, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int. 2004;15:792-798. (Pubitemid 39361949)
3. Boniva Product Labeling. vol v3.13, March 2005.
4. Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res. 2005;20:1315-1322. (Pubitemid 41033514)
5. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc. 2005;80:856-861. (Pubitemid 40911458)
6. Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med. 2006; 119(4 Suppl 1):S12-S17.
7. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005;21:1453-1460. (Pubitemid 41368578)
8. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005;165:2414-2419. (Pubitemid 41640855)
9. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007;167:540-550. (Pubitemid 46513223)
10. Gold DT, Safi W, Trinh H. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin. 2006;22:2383-2391. (Pubitemid 46055201)
11. Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin. 2005;21:1895-1903. (Pubitemid 41803098)
12. Adamson DM, Chang S, Hansen LG. Health Research Data for the Real World: The MarketScan Databases. White Paper. Ann Arbor, MI: Thomson Medstat; 2005.
13. MarketScan Research Databases User Guide and Database Dictionary. Ann Arbor, MI: Thomson Medstat; 2006.
14. Andrade SE, Gurwitz JH, Chan KA, et al. Validation of diagnoses of peptic ulcers and bleeding from administrative databases: a multi-health maintenance organization study. J Clin Epidemiol. 2002;55:310-313. (Pubitemid 34195528)
15. Ash AS, Ellis RP, Pope GC, et al. Using diagnoses to describe populations and predict costs. Health Care Financ Rev. 2000;21:7-28.
16. Zhao Y, Ellis RP, Ash AS, et al. Measuring population health risks using inpatient diagnoses and outpatient pharmacy data. Health Serv Res. 2001;36(6 Pt 2):180-193.
17. Cooper A, Drake J, Brankin E. Treatment persistence with once-monthly ibandronate and patient support vs once-weekly alendronate: results from the PERSIST study. Int J Clin Pract. 2006;60:896-905. (Pubitemid 44082279)
18. Weiss TW, Henderson SC, McHorney CA, Cramer JA. Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Curr Med Res Opin. 2007;23:2193-2203. (Pubitemid 350246605)
19. Simon J, Beusterien K, Kline Leidy N, Hebborn A. Women with postmenopausl osteoporosis express a preference for once-monthly ibandronate versus once-weekly bisphosphonate treatment. Female Patient. 2005;30:31-36.
20. Briesacher BA, Andrade SE, Yood RA, Kahler KH. Consequences of poor compliance with bisphosphonates. Bone. 2007;41:882-887. Epub 2007 Jul 18. (Pubitemid 47593009)
21. Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int. 2003;14:965-968. (Pubitemid 40824268)
22. Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med. 2003;115:209-216. (Pubitemid 37338146)